首页> 外国专利> New oligonucleotides that inhibit expression of the leptin receptor related protein, useful for treatment and prevention of e.g. osteoporosis, obesity, diabetes, anorexia, hematopoiesis, and angiogenesis

New oligonucleotides that inhibit expression of the leptin receptor related protein, useful for treatment and prevention of e.g. osteoporosis, obesity, diabetes, anorexia, hematopoiesis, and angiogenesis

机译:抑制瘦素受体相关蛋白表达的新的寡核苷酸,可用于治疗和预防例如链球菌。骨质疏松症,肥胖症,糖尿病,厌食症,造血作用和血管生成

摘要

Oligonucleotides (ON), optionally modified and comprising 8-50 nucleotides (nt), that hybridize specifically to a 648 base pair (bp) sequence (1), given in the specification, and that inhibit expression of the leptin receptor related protein (OB-RGRP), are new. Independent claims are also included for the following: (1) interfering RNA (iRNA) of 15-25 nt that hybridize specifically with a 1114 bp sequence (21), reproduced, and inhibit expression of OB-RGRP; (2) vector that expresses ON or iRNA; (3) cell containing the vector of (2); (4) pharmaceutical composition containing ON, iRNA, the vector of (2) or the cell of (3); (5) fusion protein (FP) comprising a sequence with at least 65% identify with sequences (4) or (16), both of 131 amino acids (aa), or a substantial part of them, and a protein that is a donor or acceptor of energy, or a substantial part of it; (6) nucleic acid (I) that encodes FP; (7) nucleic acid with at least 65% identity with (I) or that hybridizes to it under stringent conditions; (8) cells that contain (I), or express FP, also their fragments, lysates and membranes; (9) methods for determining modified interaction between (4) or (13), or their homologs with at least 65% identity, and the leptin receptor; and (10) method for screening or detecting compounds that can be used to prevent or treat leptin-related disorders. ACTIVITY : Osteopathic; Anorectic; Antidiabetic; Cytostatic; Antiinflammatory; Immunomodulatory; Anabolic; Endocrine-Gen.; Antianemic; Antiangiogenic. MECHANISM OF ACTION : Inhibiting expression of OB-RGRP. HeLa cells were transformed with a vector that expressed the leptin receptor (OB-R) and a reporter gene (STAT3) and with an antisense agent, AS14, directed specifically against the OB-R related protein 3'-(triethylene glycol)-TGtAcAcGtGtAcGCcGtAa (AS14) (upper case indicates phosphorothioate; the five bases at each end are 2'-O-methylated). In absence of AS14, STAT3 activity was increased by 50% in presence of leptin, but in presence of AS14, leptin almost doubled STAT3 activity.
机译:寡核苷酸(ON),经过选择性修饰,包含8-50个核苷酸(nt),可与说明书中给出的648个碱基对(bp)序列(1)特异性杂交,并抑制瘦蛋白受体相关蛋白(OB)的表达-RGRP),是新的。还包括以下方面的独立权利要求:(1)15-25 nt的干扰RNA(iRNA),可与1114 bp序列特异性杂交(21),可复制并抑制OB-RGRP的表达; (2)表达ON或iRNA的载体; (3)包含(2)的载体的细胞; (4)药物组合物,其含有ON,iRNA,(2)的载体或(3)的细胞。 (5)融合蛋白(FP),其包含具有至少65%的序列与131个氨基酸(aa)或它们的主要部分中的序列(4)或(16)和作为供体的蛋白质相同或能源的接受者,或其中很大一部分; (6)编码FP的核酸(I); (7)与(I)具有至少65%同一性或在严格条件下与其杂交的核酸; (8)含有(I)或表达FP及其片段,裂解物和膜的细胞; (9)确定(4)或(13)或其至少65%同一性的同源物与瘦素受体之间的相互作用的方法; (10)筛选或检测可用于预防或治疗瘦素相关疾病的化合物的方法。活动:整骨疗法;厌食的;抗糖尿病细胞抑制消炎(药;免疫调节合成代谢内分泌根抗贫血;抗血管生成。作用机理:抑制OB-RGRP的表达。用表达瘦蛋白受体(OB-R)和报告基因(STAT3)的载体和反义试剂AS14(分别针对OB-R相关蛋白3'-(三甘醇)-TGtAcAcGtGtAcGCcGtAa的反义剂AS14转化HeLa细胞) (AS14)(大写表示硫代磷酸酯;两端的5个碱基为2'-O-甲基化)。在没有AS14的情况下,在存在瘦素的情况下STAT3活性增加了50%,但是在存在AS14的情况下,瘦蛋白几乎使STAT3活性增加了一倍。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号